ECM
RIGL icon

Elgethun Capital Management’s Rigel Pharmaceuticals RIGL Stock Holding History

Elgethun Capital Management’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-269
Closed -$6K – 191
2016
Q4 		$6K Buy
+269
New +$7.71K ﹤0.01% 235

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Elgethun Capital Management's RIGL Position: Q1 2017 in Review

Elgethun Capital Management sold out of Rigel Pharmaceuticals (RIGL) in Q1 2017, closing a stake of 269 shares — an estimated $6K sold.

Elgethun Capital Management first reported a position in RIGL in Q4 2016 and held it in 1 quarter. The position peaked at $6K in Q4 2016. 99 funds tracked by Wall St. Rank hold RIGL as of Q1 2017.

  • Elgethun Capital Management reported no remaining Rigel Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Elgethun Capital Management sold 269 Rigel Pharmaceuticals shares in Q1 2017, an estimated $6K.
  • Elgethun Capital Management first reported a position in Rigel Pharmaceuticals in Q4 2016 and held it in 1 quarter.
  • Elgethun Capital Management's Rigel Pharmaceuticals position peaked at $6K in Q4 2016.
  • 99 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2017.

Based on Elgethun Capital Management's 13F filing for Q1 2017, filed 11 May 2017.